Once the mechanism has been described by a team from IDIBELL, ICO, HUB, and UAB, new strategies can be designed to alleviate the adverse effects of Cisplatin, one of the most common drugs in chemoth...
Read moreResearchers at IRB Barcelona’s Cellular Plasticity and Disease Laboratory propose a more efficient way to limit cell plasticity without causing cell damage. The new method sheds light on processe...
Read moreÓscar Fernández-Capetillo, jefe del Grupo de Inestabilidad Genómica, recibe 300.000 euros para estudiar el potencial de la proteína SETD8 como diana en cáncer. SETD8 se ha relacionado con e...
Read moreThe IDIBELL group led by Dr. Julián Cerón has received an “Ideas Semilla” grant from the Spanish Association Against Cancer (AECC). These grants are addressed at innovative projects tha...
Read moreFunds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials
Read moreUn trabajo liderado por la U707 CIBERER que lidera Luisa Botella en el Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC) muestra la acción de dos agentes betabloqueantes en células de...
Read moreTelstar’s cutting-edge technologies and integrated process equipment & systems covering all the critical phases of the oncology production are designed according to the higher requirements of qualit...
Read moreEn el contexto actual de desigualdades económicas y sociales existentes en muchos países europeos en relación con la atención del cáncer, es fundamental dar con soluciones accesibles que mejoren ...
Read moreHoy, desde Alma Medical Imaging, queremos hablarte del papel de la tecnología en la detección y el tratamiento del cáncer.
Read moreCancer driver genes are those with mutations that are essential for tumour development and spread. Led by ICREA researcher Patrick Aloy, scientists from the Structural Bioinformatics and Network Bi...
Read moreLAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 millio...
Read moreEl centro permite el acceso a tratamientos de vanguardia para todo tipo de pacientes oncológicos, gracias a tecnologías de última generación.
Read more